CommercialJohnson Matthey Sells Medical Metal Unit to Montagu in...

Johnson Matthey Sells Medical Metal Unit to Montagu in $700M Deal

-

Johnson Matthey, a British corporation specializing in metals and chemicals, is preparing to divest its global Medical Device Components (MDC) division, which encompasses manufacturing facilities in the United States, Mexico, and Australia. The transaction, valued at £550 million (approximately $700 million USD), will result in the transfer of ownership to Montagu Private Equity. This strategic decision follows recent moves by Johnson Matthey, including the separation of Cook Medical’s biotech unit in January, which subsequently merged with RTI Surgical.

Following the completion of the transaction, MDC will operate autonomously under its current management, overseen by Montagu. Don Freeman, MDC’s chief, expressed confidence in the partnership with Montagu, highlighting their expertise in healthcare and shared vision for the company’s growth through both organic expansion and mergers and acquisitions.
MDC specializes in the production of intricate hardware components, including micromachined and wire parts made from various metals such as nitinol alloys, platinum, titanium, and other precious materials. These components are essential in the manufacturing of medical devices such as catheter electrodes, stents, heart valves, pacemakers, neuromodulation devices, cochlear implants, and orthopedic implants. Notably, MDC contributed £93 million in revenue to Johnson Matthey for the fiscal year ending March 31, 2023.
The divestiture of MDC aligns with Johnson Matthey’s strategic realignment, which prioritizes core businesses such as clean air equipment, platinum metals services, catalyst manufacturing, and hydrogen fuel cell technologies. Montagu Partner Adrien Sassi highlighted MDC’s unique capabilities and expressed confidence in its growth potential under Montagu’s ownership.

This divestiture is part of Johnson Matthey’s broader restructuring initiative, initiated in 2022, with the aim of optimizing operations and portfolio management. In the 2023 fiscal year, the MDC division, along with other value businesses such as battery systems, diagnostic services, and advanced glass technologies, collectively generated 470 million euros in sales. CEO Liam Condon reiterated Montagu’s commitment to sustaining MDC’s growth trajectory, revealing plans to utilize the sale proceeds for debt reduction and to support corporate objectives.

Life Sciences Voice Logo mobile
+ posts

Latest news

Definium Bags Major Phase 3 Victory With LSD Formula

Definium Therapeutics has scored another phase 3 success with its LSD-based therapy, this time demonstrating positive results in generalized...

Oregon Study Finds Triple-Drug Regimen Kept Infant Macaques HIV-Free for One Year

New research involving infant macaques has produced findings that may support further investigation of CytoDyn’s CCR5-targeting antibody leronlimab in...

Why Data Is Becoming Pharma’s Most Valuable Asset

Pharma's:Executive Summary For decades, pharmaceutical companies have built competitive advantage around scientific expertise, intellectual property, manufacturing capabilities, commercial reach, and...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you